Home
HelpTest Code TOPU Targeted Opioid Mass Spectrometry Screen, Random, Urine (Non-Orderable)
Specimen Required
Only orderable as part of profile. For more information see:
CSMHP / Controlled Substance Monitoring Hybrid Plus Drug Profile, 19 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
PMHPU / Pain Management Hybrid Profile, 22 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube: Plastic urine container
Submission Container/Tube: Plastic, 5-mL tube
Specimen Volume: 1 mL
Collection Instructions:
1. Collect a random urine specimen.
2. No preservative
Useful For
Only orderable as part of profile. For more information see:
CSMHP / Controlled Substance Monitoring Hybrid Plus Drug Profile, 19 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
PMHPU / Pain Management Hybrid Profile, 22 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
Qualitatively (present vs not detected) identifying 31 opioid compounds (parent drug and metabolites) in urine to help determine compliance or identify illicit opioid drug use
This test is not intended for use in employment-related testing.
Method Name
Only orderable as part of profile. For more information see:
CSMHP / Controlled Substance Monitoring Hybrid Plus Drug Profile, 19 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
PMHPU / Pain Management Hybrid Profile, 22 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
Liquid Chromatography Tandem Mass Spectrometry, High-Resolution Accurate Mass (LC-MS/MS HRAM)
Reporting Name
Targeted Opioid MS Screen, USpecimen Type
UrineSpecimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Urine | Refrigerated (preferred) | 14 days |
| Frozen | 28 days | |
| Ambient | 72 hours |
Reject Due To
| Gross hemolysis | Reject |
| Gross icterus | Reject |
Clinical Information
Opioids are a large class of medications commonly used to relieve acute and chronic pain or help manage opioid abuse and dependence. Medications that fall into this class include buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, tapentadol, tramadol, and others. Opioids work by binding to the opioid receptors that are found in the brain, spinal cord, gastrointestinal tract, and other organs.
Common side effects of opioids include drowsiness, confusion, nausea, constipation, and, in severe cases, respiratory depression. These are dose dependent and vary with tolerance. These medications can also produce physical and psychological dependence and have a high risk for abuse and diversion, which is one of the main reasons many professional practice guidelines recommend compliance testing in patients prescribed these medications.
Opioids are readily absorbed from the gastrointestinal tract, nasal mucosa, lungs, and after subcutaneous or intermuscular injection. Opioids are primarily excreted from the kidney in both free and conjugated forms. This assay does not hydrolyze the urine sample and looks for both parent drugs and metabolites (including glucuronide forms). The detection window for most opioids in urine is approximately 1 to 3 days with longer detection times for some compounds (ie, methadone).
Reference Values
Only orderable as part of profile. For more information see:
CSMHP / Controlled Substance Monitoring Hybrid Plus Drug Profile, 19 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
PMHPU / Pain Management Hybrid Profile, 22 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
Not detected (Positive results are reported with qualitative "Present" results)
Cutoff concentrations:
Codeine: 25 ng/mL
Codeine-6-beta-glucuronide: 100 ng/mL
Morphine: 25 ng/mL
Morphine-6-beta-glucuronide: 100 ng/mL
6-Monoacetylmorphine: 25 ng/mL
Hydrocodone: 25 ng/mL
Norhydrocodone: 25 ng/mL
Dihydrocodeine: 25 ng/mL
Hydromorphone: 25 ng/mL
Hydromorphone-3-beta-glucuronide: 100 ng/mL
Oxycodone: 25 ng/mL
Noroxycodone: 25 ng/mL
Oxymorphone: 25 ng/mL
Oxymorphone-3-beta-glucuronide: 100 ng/mL
Noroxymorphone: 25 ng/mL
Fentanyl: 2 ng/mL
Norfentanyl: 2 ng/mL
Meperidine: 25 ng/mL
Normeperidine: 25 ng/mL
Naloxone: 25 ng/mL
Naloxone-3-beta-glucuronide: 100 ng/mL
Methadone: 25 ng/mL
2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine: 25 ng/mL
Tramadol: 25 ng/mL
O-desmethyltramadol: 25 ng/mL
Tapentadol: 25 ng/mL
N-desmethyltapentadol: 50 ng/mL
Tapentadol-beta-glucuronide: 100 ng/mL
Buprenorphine: 5 ng/mL
Norbuprenorphine: 5 ng/mL
Norbuprenorphine glucuronide: 20 ng/mL
Interpretation
If an opioid or its corresponding metabolites are identified (present), it indicates that the patient has used the respective opioid in the recent past. The absence of expected opioids or their metabolites may indicate noncompliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted or adulterated urine, or limitations of testing. The concentration of the drug must be greater than or equal to the cutoff to be reported as present. If a specific drug concentration is required, the laboratory must be contacted within 2 weeks of specimen collection/testing to request quantification by a second analytical technique at an additional charge.
Cautions
No significant cautionary statements
Clinical Reference
1. Gutstein HB, Akil H. Opioid analgesics. In: Brunton LL, Lazo JS, Parker KL. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill; 2006:chap 21
2. Rovine T, Ferrero CL, American Pain Society. Chronic Pain in America: Roadblocks to Relief. Roper Starch Worldwide, Inc; 1999. Updated October 2, 2001. Accessed September 8, 2026. Available at http://accurateclinic.com/wp-content/uploads/2016/04/Chronic-Pain-In-America-Roadblocks-To-Relief-1999.pdf
3. Magnani B, Kwong T. Urine drug testing for pain management. Clin Lab Med. 2012;32(3):379-390. doi:10.1016/j.cll.2012.07.001
4. Langman LJ, Bechtel LK, Holstege CP. Clinical toxicology. In: Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, eds. Tietz Textbook of Laboratory Medicine. 7th ed. Elsevier; 2023:chap 43
5. Jannetto PJ, Bratanow NC, Clark WA, et al. Executive Summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline-using clinical laboratory tests to monitor drug therapy in pain management patients. J Appl Lab Med. 2018;2(4):489-526
Method Description
The urine sample is diluted with internal standard and then analyzed by liquid chromatography tandem mass spectrometry using a high-resolution accurate mass orbitrap detector.(Unpublished Mayo method)
Day(s) Performed
Monday through Sunday
Report Available
2 to 4 daysSpecimen Retention Time
14 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
G0481
80364 (if appropriate for select payers)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| TOPU | Targeted Opioid MS Screen, U | 95796-9 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 624213 | Codeine | 19411-8 |
| 624214 | Codeine-6-beta-glucuronide | 89310-7 |
| 624215 | Morphine | 19597-4 |
| 624216 | Morphine-6-beta-glucuronide | 89308-1 |
| 624217 | 6-monoacetylmorphine | 19321-9 |
| 624218 | Hydrocodone | 19482-9 |
| 624219 | Norhydrocodone | 89304-0 |
| 624220 | Dihydrocodeine | 19446-4 |
| 624221 | Hydromorphone | 19486-0 |
| 624222 | Hydromorphone-3-beta-glucuronide | 89309-9 |
| 624223 | Oxycodone | 19642-8 |
| 624224 | Noroxycodone | 89303-2 |
| 624225 | Oxymorphone | 19646-9 |
| 624226 | Oxymorphone-3-beta-glucuronide | 89301-6 |
| 624227 | Noroxymorphone | 89302-4 |
| 624228 | Fentanyl | 59673-4 |
| 624229 | Norfentanyl | 43199-9 |
| 624230 | Meperidine | 19532-1 |
| 624231 | Normeperidine | 27920-8 |
| 624232 | Naloxone | 42618-9 |
| 624233 | Naloxone-3-beta-glucuronide | 89307-3 |
| 624234 | Methadone | 19550-3 |
| 624235 | EDDP | 93495-0 |
| 624236 | Tramadol | 19710-3 |
| 624237 | O-desmethyltramadol | 86453-8 |
| 624238 | Tapentadol | 72485-6 |
| 624239 | N-desmethyltapentadol | 89306-5 |
| 624240 | Tapentadol-beta-glucuronide | 89300-8 |
| 624241 | Buprenorphine | 93494-3 |
| 624242 | Norbuprenorphine | 82371-6 |
| 624243 | Norbuprenorphine glucuronide | 89305-7 |
| 624244 | 69050-3 |